Compugen Ltd
CGEN Real Time Price USDRecent trades of CGEN by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by CGEN's directors and management
No recent Insider Trading for this ticker
Insider Trading DashboardGovernment lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Triple combination antibody therapies Nov. 26, 2024
-
Patent Title: Anti-pvrig antibodies and methods of use Oct. 24, 2023
-
Patent Title: Pvrig polypeptides and methods of treatment Oct. 24, 2023
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Jul. 18, 2023
-
Patent Title: Anti-pvrig antibodies and methods of use Apr. 11, 2023
-
Patent Title: Triple combination antibody therapies Jan. 18, 2022
-
Patent Title: Anti-pvrig antibodies and methods of use Jan. 11, 2022
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Aug. 25, 2020
-
Patent Title: Pvrig polypeptides and methods of treatment Feb. 04, 2020
-
Patent Title: Anti-pvrig antibodies and methods of use Jul. 16, 2019
-
Patent Title: Anti-pvrig antibodies and methods of use Mar. 12, 2019
-
Patent Title: Anti-tigit anibodies, anti-pvrig antibodies and combinations thereof Feb. 26, 2019
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Nov. 13, 2018
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Oct. 16, 2018
-
Patent Title: Anti-pvrig antibodies and methods of use Jul. 25, 2017
-
Patent Title: C10rf32 antibodies, and uses thereof for treatment of cancer Apr. 11, 2017
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jan. 31, 2017
-
Patent Title: Heparanase splice variant Aug. 30, 2016
-
Patent Title: Polypeptides and uses thereof for treatment of autoimmune disorders and infection Aug. 30, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer Aug. 09, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jun. 28, 2016
-
Patent Title: Soluble vegfr-1 variants for diagnosis of preeclampsia May. 24, 2016
-
Patent Title: Angiopoietin derived peptides Feb. 09, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Aug. 18, 2015
-
Patent Title: Compositions and methods for treatment of drug resistant multiple myeloma Apr. 07, 2015
-
Patent Title: Bioactive peptides and methods of using same Mar. 24, 2015
-
Patent Title: Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands Sep. 09, 2014
-
Patent Title: Clusterin derived peptide Nov. 05, 2013
-
Patent Title: Angiopoietin derived peptides Sep. 10, 2013
-
Patent Title: Gp96 derived peptides Aug. 20, 2013
-
Patent Title: Bioactive peptides and methods of using same Jul. 23, 2013
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Apr. 09, 2013
-
Patent Title: Peptide ligands for g-protein coupled receptors Jan. 08, 2013
-
Patent Title: Polynucleotides encoding polypeptides and methods using same May. 10, 2011
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Mar. 15, 2011
-
Patent Title: Peptides which bind to g protein-coupled receptors Feb. 08, 2011
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis Nov. 30, 2010
-
Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Jul. 20, 2010
-
Patent Title: Human thrombospondin polypeptide Jun. 29, 2010
-
Patent Title: Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof Jun. 22, 2010
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease May. 11, 2010
-
Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Mar. 16, 2010
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Feb. 23, 2010
-
Patent Title: Variants of human glycoprotein hormone alpha chain: compositions and uses thereof Feb. 02, 2010
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of CGEN in WallStreetBets Daily Discussion
Recent insights relating to CGEN
Recent picks made for CGEN stock on CNBC
ETFs with the largest estimated holdings in CGEN
Shareholder
|
Shares Held
|
---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.